Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia
暂无分享,去创建一个
Joy Tan | Hany Ariffin | Chonglei Bi | Junli Yan | A. Yeoh | H. Ariffin | Junli Yan | W. Chng | Zhenhua Li | Yi Lu | Wee-Joo Chng | Gaofeng Huang | J. Tan | Gaofeng Huang | Jim Liang-Seah Tay | Baohong Lin | Tae-Hoon Chung | Nan Jiang | Jim L-S Tay | Grace S Koh | Zhenhua Li | Yi Lu | Shirley K Y Kham | Allen E J Yeoh | S. Kham | B. Lin | Tae-Hoon Chung | Nan Jiang | G. S. Koh | Chonglei Bi
[1] D. Campana,et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Armstrong,et al. miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. , 2008, Blood.
[3] W. Hop,et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.
[4] Liang-Hu Qu,et al. MicroRNA Patterns Associated with Clinical Prognostic Parameters and CNS Relapse Prediction in Pediatric Acute Leukemia , 2009, PloS one.
[5] Yimin Xiong,et al. Identification of hsa-miR-335 as a Prognostic Signature in Gastric Cancer , 2012, PloS one.
[6] T. Yanase,et al. Modification of glucocorticoid sensitivity by MAP kinase signaling pathways in glucocorticoid-induced T-cell apoptosis. , 2006, Experimental hematology.
[7] Ronit Vogt Sionov,et al. Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. , 2008, Advances in cancer research.
[8] S. Lowe,et al. The microcosmos of cancer , 2012, Nature.
[9] A. Zelenetz,et al. Acute lymphoblastic leukemia. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[10] A. Borkhardt,et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. , 1999, Blood.
[11] W. Gerald,et al. Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.
[12] I. Rigoutsos. New tricks for animal microRNAS: targeting of amino acid coding regions at conserved and nonconserved sites. , 2009, Cancer research.
[13] J. Martinez-Climent,et al. Epigenetic regulation of miRNA genes in acute leukemia , 2012, Leukemia.
[14] M. Relling,et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. , 2011, Blood.
[15] F. Chew,et al. BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia. , 2011, Experimental hematology.
[16] Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998 .
[17] Andreas Rimner,et al. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. , 2011, Genes & development.
[18] John P A Ioannidis,et al. Clinical outcome prediction by microRNAs in human cancer: a systematic review. , 2012, Journal of the National Cancer Institute.
[19] M. Brassesco,et al. MicroRNA expression and activity in pediatric acute lymphoblastic leukemia (ALL) , 2012, Pediatric blood & cancer.
[20] Nicholas T. Ingolia,et al. Mammalian microRNAs predominantly act to decrease target mRNA levels , 2010, Nature.
[21] Stephen L. Abrams,et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.
[22] Sung-Liang Yu,et al. MicroRNA signature predicts survival and relapse in lung cancer. , 2008, Cancer cell.
[23] S. Grant,et al. MEK Inhibitors Potentiate Dexamethasone Lethality in Acute Lymphoblastic Leukemia Cells through the Pro-apoptotic Molecule BIM , 2009, Leukemia.
[24] R. Siebert,et al. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Kristen M. Jacobsen,et al. Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia. , 2009, Blood.
[26] Ling Xu,et al. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL , 2011, Human molecular genetics.
[27] Caifu Chen,et al. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia , 2011, Haematologica.
[28] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[29] F Lampert,et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. , 1998, Blood.
[30] C. Schneider,et al. miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53-dependent stress response. , 2010, Cancer research.
[31] J. Downing,et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.
[32] R. Pieters,et al. Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale , 2011, Leukemia.